Mild Cognitive Impairment and Psychopathology

Starting soon

Conditions studied: Mild Cognitive Impairment (MCI)

In brief

Mild Cognitive Impairment (MCI) is a condition characterized by cognitive deterioration greater than what is expected from normal aging, representing an important risk factor for the development of dementia. Early assessment of cognitive functions is therefore essential for promptly identifying any signs of decline. In addition to cognitive aspects, it is equally important to consider the possible psychopathological profile of patients, as such disorders can significantly influence the progression of the disease, quality of life, and the ability to manage daily activities. This protocol aims to explore the presence of psychopathological disorders in patients with MCI, with particular attention to their impact on awareness of cognitive deficits (anosognosia) and on the subjective perception of difficulties in daily life, especially in social and work contexts. The study seeks to outline a comprehensive picture of the psychopathological profile in patients with MCI, facilitating the identification of targeted and personalized interventions capable of improving clinical management and the overall well-being of the individual.

Key facts

Study ID

NCT07358962

Run by

IRCCS Centro Neurolesi Bonino Pulejo

People needed

118

Starts

2026-01-12

Expected to finish

2027-01-12

Last updated by the study team

2026-01-22

Who can join

Age: 50 and older, up to 72. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age between 50 and 72 years;
• Diagnosis of Mild Cognitive Impairment (MCI), with referral to the Neuropsychology clinic for an initial evaluation or for clinical monitoring;
• Absence of behavioral, psychiatric, or sensory disorders that could significantly compromise the performance of cognitive tests or the completion of questionnaires.

You may not qualify if…

• Neurological disorders other than MCI, such as recent stroke, severe traumatic brain injury, epilepsy, multiple sclerosis, or other atypical neurodegenerative diseases;
• Major psychiatric comorbidities not stabilized at the time of the assessment (e.g., schizophrenia, bipolar disorder in an active phase, untreated severe depression);
• Severe uncorrected sensory deficits (visual or hearing) capable of compromising the validity of cognitive and functional assessments;
• Use of medications with significant potential cognitive impact (e.g., sedatives, high-dose antipsychotics) not stabilized at the time of the assessment;
• Terminal-stage internal or oncological diseases, or other medical conditions that significantly interfere with the assessment procedures.

Where it is running

• Irccs Centro Neurolesi Bonino Pulejo — Messina, Me, Italy

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.